Form 4: Krystal Biotech Director Dino A. Rossi Acquires Stock Options
SEC Form 4 Filing
Director Dino A. Rossi acquired stock options in Krystal Biotech, Inc. on June 30, 2024.
Summary
- Dino A. Rossi, a director of Krystal Biotech, Inc., reported a transaction involving derivative securities.
- On June 30, 2024, Rossi acquired stock options representing the right to buy 5,000 shares of Krystal Biotech common stock at a price of $183.64 per share.
- The options vest in equal monthly tranches over a one-year period and expire on June 30, 2034.
- Following the transaction, Rossi directly owns 5,000 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider transactions.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- Shareholders may view this transaction as a sign of confidence from a company director.
Key Dates
| Date | Description |
|---|---|
| 06/30/2024 | Date of stock option award and transaction. |
| 06/30/2034 | Expiration date of the stock options. |
| 07/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.